Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant fa (Q39976567)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant fa |
scientific article |
Statements
1 reference
Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant fa (English)
1 reference
M Matysiak
1 reference
J Lusher
1 reference
M Recht
1 reference
L Nemes
1 reference
M Manco-Johnson
1 reference
M Smith
1 reference
P Mannucci
1 reference
C Hay
1 reference
T Abshire
1 reference
A O'Brien
1 reference
B Hayward
1 reference
C Udata
1 reference
D A Roth
1 reference
S Arkin
1 reference
9 April 2009
1 reference
1 reference
15
1 reference
4
1 reference
869-880
1 reference
Identifiers
1 reference
1 reference